News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
Novo's Wegovy pill hits $354M in Q1, beats estimates by 95%
The oral GLP-1 drug generated 2 million prescriptions since January launch, prompting Novo to revise full-year guidance upward as it competes with Lilly.
Bayer buys Perfuse for $2.45B to expand eye drug portfolio
The deal centers on a mid-stage glaucoma therapy and marks Bayer's first pharma acquisition in years, potentially its largest since AskBio in 2020.
CellCentric raises $220M Series D for myeloma pill
22-year-old biotech secures funding to target patients who have exhausted all other treatment options.
GSK signs $1B siRNA deal with China's SiranBio
British pharma giant doubles down on cardiometabolic treatments through partnership with Suzhou-based startup in crowded obesity space.
Avalo raises $375M after Phase 2 trial win in skin disorder
Biotech secured mid-stage success for experimental drug targeting inflammatory skin conditions as part of broader comeback strategy.
ParcelBio raises $13M for mRNA delivery tech
Two ex-Orbital scientists claim breakthrough in mRNA delivery, launch startup with seed funding to address technical bottlenecks.
Madrigal's MASH drug Rezdiffra beats Q1 estimates by $10M
Rezdiffra posted $311 million in first quarter sales, exceeding analyst projections in a competitive liver disease market.
OpenAI health policy blueprint serves company interests
Policy recommendations released with ChatGPT for Clinicians are reasonable but disproportionately benefit OpenAI, according to health policy experts.
AI health models need better training data, STAT report finds
STAT's AI Prognosis newsletter examines what quality health data would look like for training useful medical AI models.
Trump revives Biden AI safety rules after Anthropic model alarms
White House creates working group for pre-release model reviews after Anthropic's Mythos demonstrates concerning cybersecurity exploit capabilities.
Agent workloads consume 15x more tokens, break standard serving
NVIDIA details how agentic systems spawn sub-agents and hit 156K context windows, requiring specialized infrastructure to avoid economic collapse.
NVIDIA packages vehicle AI stack from cloud routing to edge inference
DRIVE AGX platforms now handle 7B+ parameter models locally while orchestrating with cloud agents for complex tasks like trip planning.